Updated: January 4, 2026
Padcev Access Update: What Patients Need to Know in 2026
Author
Peter Daggett
ChatGPT
Claude
Gemini
Overview
Padcev is not in FDA shortage but patients still face access barriers in 2026. Get the latest on insurance, pricing, availability, and patient assistance programs.
Is Padcev in stock near you?
Medfinder checks real pharmacy inventory — start a search and we'll find Padcev near you.
Padcev (enfortumab vedotin-ejfv) is not currently listed on the FDA Drug Shortage Database. Unlike some medications where patients compete for limited pharmacy supply, Padcev's access challenges in 2026 are primarily about insurance coverage, prior authorization, and access to specialized infusion centers — not a physical shortage of the drug itself.
However, that doesn't mean access is easy. Here's what patients need to know about Padcev availability and how to navigate any barriers in 2026.
Is Padcev in Shortage in 2026?
No. As of 2026, Padcev is not in shortage. The drug continues to be manufactured by Astellas Pharma and distributed through specialty distribution networks to hospital and outpatient infusion centers. If your infusion center says Padcev is unavailable on a specific date, this is typically a stocking or scheduling issue, not a national shortage.
Because Padcev is a high-cost specialty biologic, many infusion centers order it on a patient-by-patient basis rather than maintaining large standing inventory. This means your oncology team typically needs to confirm your appointment and insurance before ordering the drug. Plan accordingly and give your care team advance notice.
Check live stock now.
How Has the Approval History of Padcev Changed Access?
Padcev has undergone significant label expansions since its initial accelerated approval in December 2019. The biggest milestone was the full FDA approval in December 2023 for use in combination with pembrolizumab for locally advanced or metastatic urothelial cancer — based on impressive results from the EV-302/KEYNOTE-A39 trial showing a median overall survival of 31.5 months compared to 16.1 months with chemotherapy.
In 2025, additional approvals expanded Padcev's indication to include use in the neoadjuvant and adjuvant settings for muscle-invasive bladder cancer (MIBC) in patients ineligible for cisplatin. These expanded indications mean more patients are eligible for Padcev — which also means more insurance coverage decisions need to be navigated.
What Are the Main Access Barriers for Padcev Patients in 2026?
Insurance prior authorization (PA): The most common delay. Insurers require detailed documentation of diagnosis, staging, prior treatment, and medical necessity. PA approvals can take days to weeks.
High out-of-pocket cost: Even with insurance, cost-sharing for an infused specialty oncology drug can be substantial. A 20 mg vial has a cash price of approximately $2,793; a 30 mg vial approximately $4,185.
Geographic access: Patients in rural areas may lack access to nearby oncology infusion centers qualified to administer Padcev safely.
Medical benefit vs pharmacy benefit confusion: Padcev is billed under the medical benefit (J9177), not the pharmacy benefit. Patients with strong pharmacy plans may be surprised by this.
What Financial Assistance Is Available in 2026?
Astellas continues to offer robust financial assistance for Padcev patients:
PADCEV Copay Assistance Program: Commercially insured patients may pay as little as $5 per dose, up to a maximum of $25,000 per calendar year. Contact PADCEV Support Solutions at 1-888-402-0627 to enroll.
PADCEV Patient Assistance Program (PAP): Provides Padcev at no cost to uninsured patients who meet financial eligibility requirements. Your healthcare provider initiates the application.
Independent nonprofit foundations: Organizations such as the Patient Advocate Foundation (PAF), CancerCare, and the HealthWell Foundation may offer additional assistance for patients who don't qualify for manufacturer programs.
What Should You Do If There's a Delay in Your Padcev Treatment?
If you're facing a delay in starting or continuing Padcev:
Contact your oncologist immediately to understand the reason for delay.
Ask whether the PA appeal process has been initiated if insurance denied coverage.
Call PADCEV Support Solutions at 1-888-402-0627 to expedite access support.
Ask your oncologist about bridge therapy options while waiting for authorization.
If access continues to be blocked, learn more about Padcev alternatives for urothelial cancer to discuss options with your oncologist.
Frequently Asked Questions
Yes. Padcev is available in 2026 and is not on the FDA drug shortage list. It is manufactured by Astellas Pharma and distributed through specialty channels to infusion centers nationwide. Access challenges are primarily insurance-related rather than supply-related.
Most infusion centers order Padcev on a per-patient basis rather than maintaining standing stock, due to its high cost. If your center says it's unavailable, they likely need to confirm your insurance approval and schedule the order ahead of your appointment. Give your team 1-2 weeks advance notice before each cycle.
Padcev is typically covered under Medicare Part B (outpatient medical benefit) when administered at an approved infusion center. Part B covers most infused drugs administered by healthcare providers. Your oncologist's billing team can confirm Part B eligibility and any cost-sharing that applies.
Prior authorization for Padcev typically takes 3-14 business days, depending on your insurer and how complete the submitted documentation is. PADCEV Support Solutions (1-888-402-0627) can assist your oncologist's office in submitting a complete, timely PA request to minimize delays.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Padcev also looked for:
More about Padcev
Why Is Padcev So Hard to Access? [Explained for 2026]
How to Find Padcev in Stock Near You (Tools + Tips)
Alternatives to Padcev If You Can't Fill Your Prescription
Padcev Access Challenges: What Providers and Prescribers Need to Know in 2026
How to Help Your Patients Find Padcev in Stock: A Provider's Guide
How to Save Money on Padcev in 2026: Coupons, Discounts, and Patient Assistance
39,483 have already found their meds with Medfinder.
Start your search today.
Your information is private and never shared.